Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Pancreatic Neoplasms × Combined Modality Therapy × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 2 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Peritoneal Neoplasms 1 Pancreatic Neoplasms 1 Neuroblastoma 1 HER2 Positive Esophagogastric Cancer 1 Esophageal Squamous Cell Carcinoma 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Advanced Esophageal Cancer 1

Interventions

Gemcitabine 268 Fluorouracil 72 Oxaliplatin 70 130-nm albumin-bound paclitaxel 59 Leucovorin 51 Capecitabine 48 Radiotherapy 47 Albumin-Bound Paclitaxel 47 Irinotecan 41 Cisplatin 34 Taxes 32 Erlotinib Hydrochloride 32 pembrolizumab 26 Radiosurgery 26 Docetaxel 25 S 1 (combination) 24 Bevacizumab 21 folfirinox 18 Nivolumab 17 Radiation 15 Magnetic Resonance Spectroscopy 15 Cyclophosphamide 15 Cetuximab 15 irinotecan sucrosofate 14 Drug Therapy 12 Surgical Procedures, Operative 11 Specimen Handling 10 Biopsy 10 Paclitaxel 9 Ipilimumab 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04718701 2021-08-16

ATNPA

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡